Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice P Sonveaux, F Végran, T Schroeder, MC Wergin, J Verrax, ZN Rabbani, ... The Journal of clinical investigation 118 (12), 3930-3942, 2008 | 1914 | 2008 |
Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis F Végran, R Boidot, C Michiels, P Sonveaux, O Feron Cancer research 71 (7), 2550-2560, 2011 | 831 | 2011 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth M Bruchard, G Mignot, V Derangère, F Chalmin, A Chevriaux, F Végran, ... Nature medicine 19 (1), 57-64, 2013 | 788 | 2013 |
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis P Sonveaux, T Copetti, CJ De Saedeleer, F Vegran, J Verrax, ... PloS one 7 (3), e33418, 2012 | 567 | 2012 |
The receptor NLRP3 is a transcriptional regulator of TH2 differentiation M Bruchard, C Rebé, V Derangère, D Togbé, B Ryffel, R Boidot, ... Nature immunology 16 (8), 859-870, 2015 | 388 | 2015 |
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression F Chalmin, G Mignot, M Bruchard, A Chevriaux, F Végran, A Hichami, ... Immunity 36 (3), 362-373, 2012 | 376 | 2012 |
Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors R Boidot, F Végran, A Meulle, A Le Breton, C Dessy, P Sonveaux, ... Cancer research 72 (4), 939-948, 2012 | 270 | 2012 |
STAT3 activation: A key factor in tumor immunoescape C Rébé, F Végran, H Berger, F Ghiringhelli Jak-stat 2 (1), e23010, 2013 | 262 | 2013 |
Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX–bevacizumab drug treatment regimen E Limagne, R Euvrard, M Thibaudin, C Rébé, V Derangère, A Chevriaux, ... Cancer research 76 (18), 5241-5252, 2016 | 250 | 2016 |
The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells F Végran, H Berger, R Boidot, G Mignot, M Bruchard, M Dosset, ... Nature immunology 15 (8), 758-766, 2014 | 225 | 2014 |
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer M Dosset, TR Vargas, A Lagrange, R Boidot, F Végran, A Roussey, ... Oncoimmunology 7 (6), e1433981, 2018 | 195 | 2018 |
Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells V Derangere, A Chevriaux, F Courtaut, M Bruchard, H Berger, F Chalmin, ... Cell Death & Differentiation 21 (12), 1914-1924, 2014 | 155 | 2014 |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells H Bugaut, M Bruchard, H Berger, V Derangère, L Odoul, R Euvrard, ... PLoS One 8 (6), e65181, 2013 | 121 | 2013 |
Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth A Hervieu, C Rébé, F Végran, F Chalmin, M Bruchard, P Vabres, L Apetoh, ... Journal of Investigative Dermatology 133 (2), 499-508, 2013 | 106 | 2013 |
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy J Niogret, H Berger, C Rebe, R Mary, E Ballot, C Truntzer, M Thibaudin, ... Journal for immunotherapy of cancer 9 (6), 2021 | 100 | 2021 |
Th9 cells: a novel CD4 T-cell subset in the immune war against cancer F Végran, L Apetoh, F Ghiringhelli Cancer research 75 (3), 475-479, 2015 | 99 | 2015 |
Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer F Vegran, R Boidot, C Oudin, C Defrain, M Rebucci, S Lizard-Nacol Oncogene 26 (2), 290-297, 2007 | 99 | 2007 |
Transcriptional regulation of the survivin gene R Boidot, F Végran, S Lizard-Nacol Molecular biology reports 41, 233-240, 2014 | 98 | 2014 |
Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy F Végran, R Boidot, C Oudin, JM Riedinger, F Bonnetain, S Lizard-Nacol Clinical cancer research 12 (19), 5794-5800, 2006 | 89 | 2006 |
TH9 cells in anti-tumor immunity T Rivera Vargas, E Humblin, F Végran, F Ghiringhelli, L Apetoh Seminars in immunopathology 39 (1), 39-46, 2017 | 87 | 2017 |